Natco Pharma Limited has informed the Exchange regarding a press release dated February 05, 2021, titled "NATCO receives approval for Chlorantraniliprole (CTPR)- 1st key product of Crop Health Sciences Division".
Press Release Feb 05 2021
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from NATCO Pharma
- NATCO Pharma launches anti blood clot tablet Rivaroxaban in India
- Press Release Dec 17 2020
- NATCO Pharma receives Pomalidomide approval for US market
- Press Release Nov 13 2020
- Press Release Nov 12 2020
Later from NATCO Pharma
- NATCO Pharma receives approval for Chlorantraniliprole 1st key product of Crop Health Sciences Division
- Press Release Feb 26 2021
- NATCO Pharma launches Brivaracetam tablets, in India, for treatment of epilepsy
- Press Release Mar 08 2021
- Press Release Mar 15 2021
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma